Amneal Pharmaceuticals, Inc.
AMRX
$17.09
$0.040.24%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 9.89% | 3.90% | 11.47% | 11.68% | 3.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.89% | 3.90% | 11.47% | 11.68% | 3.24% |
| Cost of Revenue | 5.34% | -8.46% | 10.45% | 12.72% | -2.78% |
| Gross Profit | 16.95% | 25.36% | 13.32% | 9.99% | 14.19% |
| SG&A Expenses | 19.68% | 17.39% | 13.74% | 16.11% | 6.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 98.75% | -103.33% | -290.00% | -- |
| Total Operating Expenses | 6.16% | -2.25% | 7.25% | 12.46% | 1.17% |
| Operating Income | 30.33% | 40.11% | 46.73% | 6.19% | 16.20% |
| Income Before Tax | 37.28% | 113.88% | 460.57% | -133.87% | 153.42% |
| Income Tax Expenses | -91.45% | -83.09% | 4.41% | -737.07% | 345.02% |
| Earnings from Continuing Operations | 95.49% | 216.84% | 339.00% | 54.22% | 112.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 9.41% | -26.73% | -40.22% | -32.32% | -22.24% |
| Net Income | 157.22% | 410.50% | 212.85% | 1,618.59% | 273.99% |
| EBIT | 30.33% | 40.11% | 46.73% | 6.19% | 16.20% |
| EBITDA | 12.58% | 14.59% | 13.57% | 0.38% | 13.27% |
| EPS Basic | 152.59% | 402.55% | 211.17% | 1,600.00% | 268.56% |
| Normalized Basic EPS | 114.31% | 214.79% | 214.91% | 609.68% | 10,266.67% |
| EPS Diluted | 157.14% | 384.69% | 208.97% | 1,600.00% | 260.82% |
| Normalized Diluted EPS | 114.03% | 214.53% | 210.05% | 593.55% | 10,000.00% |
| Average Basic Shares Outstanding | 1.74% | 1.60% | 1.49% | 1.46% | 1.50% |
| Average Diluted Shares Outstanding | 1.78% | 1.53% | 5.89% | 4.88% | 1.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |